ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
European Medicines Agency Recommends The Approval Of Thalidomide For The Treatment Of Rare Bone-Marrow Cancer
The European Medicines Agency (EMEA) has recommended the approval of
Thalidomide Pharmion (thalidomide) for the treatment of multiple
myeloma, a rare cancer of the bone marrow.
Meeting on 21-24 January 2008, the Agency's Committee for Medicinal
Products for Human Use (CHMP) concluded that the benefits of Thalidomide
Pharmion in combination with melphalan and prednisone outweigh its risks
for the first-line treatment of multiple myeloma for patients over 65
years of age or who cannot be treated with high-dose chemotherapy.
Clinical studies have shown that adding Thalidomide Pharmion to
melphalan and prednisone can prolong survival time by about 18 months in
newly-diagnosed multiple myeloma patients over 65 years of age, as
compared to patients who received conventional chemotherapy.
Thalidomide is teratogenic. This means that there is a high risk that
severe birth defects will occur when a foetus is exposed to thalidomide
in the womb in the first part of pregnancy. Because of this, the CHMP
has consulted representatives of thalidomide victims and myeloma patient
groups from across the European Union to develop measures that can
effectively minimise the risk of foetal exposure to thalidomide.
The CHMP has approved a risk management plan that includes a number of
actions intended to prevent pregnancies in women being treated with
thalidomide and exposure of unborn children to the medicine. For
example, all women of child-bearing potential who are treated with
Thalidomide Pharmion must undergo pregnancy tests before, during and
after treatment, in addition to using selected and effective
contraception.
Subject to the granting of a marketing authorisation by the European
Commission, Thalidomide Pharmion will only be available by prescription,
and treatment will be initiated and monitored by a doctor who has
experience in the treatment of multiple myeloma. A clear warning will be
printed on the boxes containing the medicine, indicating that
Thalidomide Pharmion causes birth defects and foetal death.
Prior to the launch of Thalidomide Pharmion in each Member State,
Pharmion Ltd. will provide healthcare professionals and patients with
educational materials about the treatment-related risks and the
precautions required to ensure the safe use of the product .
Notes:
1. A separate question-and-answer document can be found here.
2. The summary of opinion for Thalidomide Pharmion can be found here.
3. Thalidomide for the treatment of multiple myeloma was designated as
an orphan medicinal product in November 2001. See here
for
the summary of the positive opinion.
4. Thalidomide is also designated as an orphan medicinal product for the
treatment of graft versus host disease. See here for
the summary of the positive opinion.
5. Thalidomide is already authorised in other countries for multiple
myeloma, including Australia and the USA.
European Medicines Agency
Agenþia Europeanã a Medicamentului recomandã aprobarea Thalidomide pentru tratamentul de rare de cancer a mãduvei osoase - - European Medicines Agency Recommends The Approval Of Thalidomide For The Treatment Of Rare Bone-Marrow Cancer - articole medicale engleza - startsanatate